Evaluation of Clinical Parameters Associated with Response and Resistance to Cemiplimab in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma: A Multi-Institutional Retrospective Cohort Study
Open Access
- 15 March 2025
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 32 (3) , 168
Abstract
Cutaneous squamous cell carcinoma (cSCC) is a common cancer with increasing incidence and 5% of patients develop incurable disease, often resistant to chemotherapy. The anti-PD-1 therapy cemiplimab has shown high efficacy in clinical trials. This retrospective study evaluated the real-world effectiveness of cemiplimab in incurable cSCC and examined factors influencing response and toxicity. Data from 86 patients across three UK healthcare providers were analysed. Median progression-free survival (PFS) and overall survival (OS) were not reached, with 38% showing durable responses beyond 12 months. The overall response rate was 60.8% (95% CI 49–71), and the clinical benefit rate was 74.3% (95% CI 63–83). A head and neck primary site was associated with improved PFS (p = 0.008) and OS (p = 0.023), while concurrent immunosuppression was associated with worse PFS (p < 0.001). These findings align with clinical trials, suggesting cemiplimab is effective and safe in the recurrent/metastatic setting.Keywords
All Related Versions
Funding Information
- Christie Charity
- Syncona Foundation
- Infrastructure Industry Foundation
This publication has 14 references indexed in Scilit:
- Predictors of Recurrence and Progression in Poorly Differentiated Cutaneous Squamous Cell Carcinomas: Insights from a Real-Life ExperienceDermatology, 2023
- Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and PerspectivesFrontiers in Oncology, 2022
- Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinomaEuropean Journal of Cancer, 2021
- Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysisJournal for ImmunoTherapy of Cancer, 2021
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 2021
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trialThe Lancet Oncology, 2020
- Cutaneous Squamous Cell CarcinomaHematology/Oncology Clinics of North America, 2019
- Tumor mutational load predicts survival after immunotherapy across multiple cancer typesNature Genetics, 2019
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine, 2018
- Factors Predictive of Recurrence and Death From Cutaneous Squamous Cell CarcinomaJAMA Dermatology, 2013